CClinicalTrials.gg
CompletedNCT02959268PRALSUpdated Oct 31, 2019

Pivotal Study of the Rx Al-Sense Liner for Amniotic Fluid Leakage Screening

An interventional study of Al-Sense in Amniotic Problems, sponsored by Common Sense. Completed at 4 sites in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-31.

Sponsored by Common Sense · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

This is a Prospective open-label, comparative pivotal study with comparison of self-assessments with blinded investigator assessments. Pregnant women attending the labor and delivery unit of the hospital or emergency clinic and reporting unidentified wetness (undetermined whether this is amniotic fluid leakage or urinary incontinence) will be enrolled in this study. After informed consent is obtained, each subject will be given a single AL-SENSE to use up to 12 hours or until the perception of wetness.

Product Usage

After usage, the subject will read and record any occurrence of color change of the AL-SENSE 10 minutes after the liner removal and to mark if it changes color to blue or to green or not on the designated form. The subjects will fill out the questionnaire regarding the product usage experience and the liner color reading with no help from the investigator, to validate IFU reading comprehension. A blinded clinician will perform a "standard clinical diagnosis" (clinical assessment). The standard clinical diagnostic methods will include the following tests: (1) Pooling test, (2) Ferning test, (3) pH test by pH paper. A positive Pooling test and/or positive results in both the pH test and the Ferning test will be defined as a positive clinical test result.

Read the detailed description

This study is designed to demonstrate that the performance of the AL-SENSE developed by Common Sense Ltd. is safe and effective and can be used to indicate if the patient may be experiencing an amniotic fluid leakage .

The AL-SENSE is an extended shelf-life product that is technically simple, fast to react, visually readable, and therefore enables women to test the cause of any unidentified wetness, before confirmation by a physician.

Principles of operation:

Vaginal fluids are discharged over time and collected on the non-intrusive panty liner. If the user observes a blue or green stain, the result of the test is positive. The AL-SENSE polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value.

The AL-SENSE will indicate that the pH level is elevated when the level is equal or greater than 6.5. This choice of 6.5 units as the cutoff level will limit the cases of false positive and will reduce unnecessary alarm.

Summary of Study Design

Design: Prospective open-label, comparative pivotal study with comparison of self-assessments with blinded investigator assessments.

Patient Population: Pregnant women, ages 18 and above.

Baseline/ Screening

Subjects attending the labor and delivery unit of the hospital or emergency clinic and reporting unidentified wetness (undetermined whether this is amniotic fluid leakage or urinary incontinence) will be enrolled in this study. After informed consent is obtained, each subject will be given a single AL-SENSE to use up to 12 hours or until the perception of wetness. The clinician will explain the proper use and handling of the AL-SENSE and how to read the result. The participants will be provided with instructions for use and also directed to read the Instructions For Use (IFU) prior to applying the AL-SENSE pad.

Product Usage

After usage, the subject will read and record any occurrence of color change of the AL-SENSE 10 minutes after the liner removal . The subjects will fill out the questionnaire regarding the product usage experience and the liner color reading with no help from the investigator, to validate IFU reading comprehension.

Clinical Diagnosis

A blinded clinician will perform a "standard clinical diagnosis" (clinical assessment), and record the results on a worksheet to be included in the case report form. The standard clinical diagnostic methods will include the following tests: (1) Pooling test, (2) Ferning test, (3) pH test by pH paper.

02

Conditions studied

  • Amniotic Problems
03

In context

Lead sponsor

Common Sense is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Screening/ Baseline inclusion criteria for subject participation in the study at baseline assessment are pregnant women age 18 and above who have completed minimum 16 weeks of pregnancy are eligible for the study. Subject attending the labor and delivery unit of the hospital or emergency clinic or outpatient clinic and reporting a feeling of vaginal wetness feeling (undetermined whether this is amniotic fluid leakage or urinary incontinence)

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
Single (Participant)
Enrollment
250 participants (actual)

Study arms

  • Other
    Single arm Al-Sense diagnostic

    Investigator blinded to subject assessments

    Device: Al-Sense

Interventions

  • DeviceAl-Sense

    Liner for diagnosis of amniotic fluid leakage verified by standard clinical diagnostic tests

06

What researchers measure

Primary outcomes

  1. Color change of pantyliner surface compared to standard clinical diagnosis

    Color change

    Time frame: 10 minutes

Secondary outcomes

  1. Questionnaire to assess subject comprehension of usage criteria and subjective experience

    Self-report of product usage experience and correct usage according to instructions for use

    Time frame: 15 minutes

  2. Subject vs. Clinician reading of liner color change

    compare subject and clinician readings

    Time frame: up to 48 hours

07

Study locations

4 sites
  • Jersey Shore University Medical Center
    Neptune, New Jersey 07753, United States
  • Rutgers Womens Health Institute
    New Brunswick, New Jersey 08901, United States
  • University Hospital Rutgers Newark
    Newark, New Jersey 07103, United States
  • Drexel University Medical School
    Philadelphia, Pennsylvania 19102, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02959268
Lead sponsor
Common Sense
Responsible party
Sponsor
First posted
Nov 9, 2016
Start date
Nov 2016
Primary completion
Oct 2017
Completion
Oct 2017
Last update
Oct 31, 2019

Study contacts

Shantala Ramachandra, MD
study director · Consultant Medical Monitor

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion